Similarly, the ATTRACTION-04 trial, a randomized multicenter Phase II/III study, demonstrated that first-line nivolumab with chemotherapy significantly improved PFS in Asian patients with HER2-negative advanced or recurrent GC (PFS: 10-45 months vs. 8-34 months; HR 0.68; 98.51% CI: 0.51-0.90; P=0.0007), suggesting it may become the new standard of care (42). The gene discussed is ERBB2; the disease is gastric cancer.